Tsai, Hui-Jen
Shiah, Her-Shyong
Chang, Jang-Yang
Su, Wu-Chou
Chiang, Nai-Jung
Chen, Li-Tzong
Article History
Received: 1 April 2020
Accepted: 25 January 2021
First Online: 1 March 2021
Competing interests
: Dr. Hui-Jen Tsai has received honoraria from Bayer HealthCare Pharmaceuticals Co., Ltd, Novartis, and Ipsen for speech. Dr. Li-Tzong Chen has received research funding from Norvatis, Merck Serono, TTY, Polaris, SyncorePharm, Pfizer, and BMS; honoraria from ONO, Eli Lilly, MSD, PharmaEngine, TTY, SyncorePharm, Norvatis, Astra Zeneca, and Ipsen; and patents & royalties from ENO-1mAb/HuniLife. Dr. Chen is also a member of the Board of Directors at ScinoPharm. Taiwan, Ltd. and is on the Scientific Advisory Committee at PharmaEngine. Dr. Her-Shyong Hsiah, Dr. Jang-Yang Chang, Dr. Wu-Chou Su, and Dr. Nai-Jung Chiang declare no competing financial interests.